Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor

Targeted Oncology

Volumn 4, Issue 4, 2009, Pages 297-305

  Kelly, Ronan J ^a   Rixe, Olivier ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Axitinib; Pancreatic carcinoma; Renal cell carcinoma; Tyrosine kinese inhibitor; VEGF receptor inhibitor

Indexed keywords

ALPHA2A INTERFERON; ANTACID AGENT; ANTIHYPERTENSIVE AGENT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; ERYTHROPOIETIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IODINE 131; IRINOTECAN; KETOCONAZOLE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXALIPLATIN; PROTON PUMP INHIBITOR; RADIOACTIVE IODINE; RIFAMPICIN; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ADENOID CYSTIC CARCINOMA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG TREATMENT FAILURE; DRY SKIN; DYSGEUSIA; DYSPEPSIA; ENZYME PHOSPHORYLATION; EPISTAXIS; ERYTHROCYTOSIS; FATIGUE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEMATOCHEZIA; HEMOPTYSIS; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; KIDNEY CARCINOMA; LIMB PAIN; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS CARCINOMA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RECTUM HEMORRHAGE; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THYROID CANCER; THYROID CARCINOMA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; IMIDAZOLES; INDAZOLES; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 72449131348     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-009-0126-9     Document Type: Review

References (49)

1. P Carmeliet RK Jain 2000 Angiogenesis in cancer and other diseases Nature 407 249 257 10.1038/35025220 1:CAS:528:DC%2BD3cXmvVSls74%3D 11001068
2. BI Rini EJ Small 2005 Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma J Clin Oncol 23 1028 1043 10.1200/JCO.2005.01.186 1:CAS:528:DC%2BD2MXit1Gnsrs%3D 15534359 (Pubitemid 46202321)
3. DJ Hicklin LM Ellis 2005 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 1011 1027 10.1200/JCO.2005.06.081 1:CAS:528:DC%2BD2MXit1Gnsro%3D 15585754 (Pubitemid 46202320)
4. N Ferrara HP Gerber J LeCouter 2003 The biology of VEGF and its receptors Nat Med 9 669 676 10.1038/nm0603-669 1:CAS:528:DC%2BD3sXktFOnur4%3D 12778165 (Pubitemid 36749215)
5. DW Leung G Cachianes WJ Kuang DV Goeddel N Ferrara 1989 Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 1306 1309 10.1126/science.2479986 1:CAS:528:DyaK3cXls1GltLo%3D 2479986
6. MJ Cross J Dixelius T Matsumoto L Claesson-Welsh 2003 VEGF-receptor signal transduction Trends Biochem Sci 28 488 494 10.1016/S0968-0004(03)00193-2 1:CAS:528:DC%2BD3sXnt1ylsLs%3D 13678960 (Pubitemid 38340413)
7. M Nilsson JV Heymach 2006 Vascular endothelial growth factor (VEGF) pathway J Thorac Oncol 1 768 770 10.1097/01243894-200610000-00003 17409958
8. BI Terman ME Carrion E Kovacs BA Rasmussen RL Eddy TB Shows 1991 Identification of a new endothelial cell growth factor receptor tyrosine kinase Oncogene 6 1677 1683 1:CAS:528:DyaK3MXmslahsrc%3D 1656371
9. SN Sait M Dougher-Vermazen TB Shows BI Terman 1995 The kinase insert domain receptor gene (KDR) has been relocated to chromosome 4q11->q12 Cytogenet Cell Genet 70 145 146 10.1159/000134081 1:CAS:528:DyaK2MXmvVWgtrk%3D 7736781
10. M Shibuya 2002 Vascular endothelial growth factor receptor family genes: when did the three genes phylogenetically segregate? Biol Chem 383 1573 1579 10.1515/BC.2002.177 1:CAS:528:DC%2BD3sXhtVyjtw%3D%3D 12452433 (Pubitemid 35282976)
11. T Takahashi M Shibuya 1997 The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts Oncogene 14 2079 2089 10.1038/sj.onc.1201047 1:CAS:528:DyaK2sXjsVKhsrw%3D 9160888
12. HS Rugo RS Herbst G Liu, et al. 2005 Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results J Clin Oncol 23 5474 5483 10.1200/JCO.2005.04.192 1:CAS:528:DC%2BD2MXhtVersr7F 16027439 (Pubitemid 46300140)
13. DD Hu-Lowe HY Zou ML Grazzini, et al. 2008 Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 14 7272 7283 10.1158/1078-0432.CCR-08-0652 1:CAS:528:DC%2BD1cXhtlylur7I 19010843
14. LJ Wilmes MG Pallavicini LM Fleming, et al. 2007 AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging Magn Reson Imaging 25 319 327 10.1016/j.mri.2006.09. 041 1:CAS:528:DC%2BD2sXjtVagur0%3D 17371720 (Pubitemid 46413652)
15. JC Yang L Haworth RM Sherry, et al. 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434 10.1056/NEJMoa021491 1:CAS:528: DC%2BD3sXms1Klu7w%3D 12890841 (Pubitemid 36910021)
16. B Escudier T Eisen WM Stadler, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D 17215530 (Pubitemid 46089673)
17. RJ Motzer MD Michaelson BG Redman, et al. 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 16 24 10.1200/JCO.2005.02.2574 1:CAS:528: DC%2BD28Xot1ChtA%3D%3D 16330672 (Pubitemid 46630489)
18. RJ Motzer TE Hutson P Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 17215529 (Pubitemid 46089672)
19. O Rixe RM Bukowski MD Michaelson, et al. 2007 Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 975 984 10.1016/S1470-2045(07)70285-1 17959415 (Pubitemid 47629888)
20. O Rixe J-B Meric J Bloch, et al. 2005 Surrogate markers of activity of AG-013736, a multi-target tyrosine kinase receptor inhibitor, in metastatic renal cell cancer (RCC) J Clin Oncol 23 3003 (Meeting Abstracts)
21. BI Rini GT Wilding G Hudes, et al. 2007 Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib J Clin Oncol 25 5032 (Meeting Abstracts)
22. HA Burris 3rd MJ Moore J Andersen, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 1:CAS:528:DyaK2sXlsFKksLY%3D 9196156
23. MJ Moore D Goldstein J Hamm, et al. 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960 1966 10.1200/JCO.2006.07.9525 1:CAS:528: DC%2BD2sXmvVWmsr0%3D 17452677 (Pubitemid 46972777)
24. PA Philip J Benedetti C Fenoglio-Preiser, et al. 2007 Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study J Clin Oncol 25 LBA4509 10.1200/JCO.2006.09.6040 (Meeting Abstracts) (Pubitemid 46596777)
25. M Korc 2003 Pathways for aberrant angiogenesis in pancreatic cancer Mol Cancer 2 8 10.1186/1476-4598-2-8 1:STN:280:DC%2BD2czltlyhsA%3D%3D 12556241 (Pubitemid 38751489)
26. Y Seo H Baba T Fukuda M Takashima K Sugimachi 2000 High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma Cancer 88 2239 2245 10.1002/(SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0.CO;2-V 1:CAS:528:DC%2BD3cXjslSqtbo%3D 10820344 (Pubitemid 30247122)
27. M Niedergethmann R Hildenbrand B Wostbrock, et al. 2002 High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas Pancreas 25 122 129 10.1097/00006676-200208000-00002 12142733 (Pubitemid 34815907)
28. HL Kindler D Niedzwiecki D Hollis, et al. 2007 A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB J Clin Oncol 25 4508 (Meeting Abstracts)
29. JP Spano C Chodkiewicz J Maurel, et al. 2008 Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study Lancet 371 2101 2108 10.1016/S0140-6736(08)60661-3 1:CAS:528:DC%2BD1cXnsFGjurs%3D 18514303
30. Phase II study of AG-013736 in combination with docetaxel versus docetaxel alone for patients with metastatic breast cancer. Clinicaltrials.gov 2006 July 25. http://clinicaltrials.gov/ct2/show/NCT00076024. Accessed on 15 Oct 2009
31. HS Rugo A Stopeck AA Joy, et al. 2007 A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC) J Clin Oncol 25 1003 10.1200/JCO.2006.09.8525 (Meeting Abstracts) (Pubitemid 350002867)
32. K Cupisti A Wolf A Raffel, et al. 2007 Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution's experience over 20 years Ann Surg 246 815 821 10.1097/SLA.0b013e31813e66b9 17968174 (Pubitemid 350035658)
33. JA Gottlieb CS Hill Jr 1974 Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients N Engl J Med 290 193 197 1:STN:280:DyaE2c%2FmtFGqug%3D%3D 4808917
34. K Shimaoka DA Schoenfeld WD DeWys RH Creech R DeConti 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma Cancer 56 2155 2160 10.1002/1097-0142(19851101)56:9<2155:: AID-CNCR2820560903>3.0.CO;2-E 1:STN:280:DyaL28%2FislOjtw%3D%3D 3902203 (Pubitemid 16236586)
35. G Viglietto D Maglione M Rambaldi, et al. 1995 Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines Oncogene 11 1569 1579 1:CAS:528:DyaK2MXptVymt7Y%3D 7478581
36. AB Kilicarslan M Ogus C Arici HE Pestereli M Cakir G Karpuzoglu 2003 Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas APMIS 111 439 443 10.1034/j.1600-0463.2003.t01-1-1110209.x 1:CAS:528:DC%2BD3sXkt1KmsLY%3D 12752224 (Pubitemid 36560544)
37. M Klein E Picard JM Vignaud, et al. 1999 Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma J Endocrinol 161 41 49 10.1677/joe.0.1610041 1:CAS:528:DyaK1MXktVekt7w%3D 10194527
38. EE Cohen LS Rosen EE Vokes, et al. 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study J Clin Oncol 26 4708 4713 10.1200/JCO.2007.15.9566 1:CAS:528: DC%2BD1cXhtlSqsLfE 18541897
39. JH Schiller T Larson SI Ou, et al. 2007 Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial J Clin Oncol 25 7507 (Meeting Abstracts)
40. JP Fruehauf J Lutzky DF McDermott, et al. 2008 Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study J Clin Oncol 26 9006 (Meeting Abstracts)
41. Phase II study with AG-013736 combined with chemotherapy and bevacizumab in patients with metastatic colorectal cancer. Clinicaltrials.gov 2008 April 17. http://clinicaltrials.gov/ct2/show/NCT00460603. Accessed 15 Oct 2009
42. A study combining FOLFOX or FOLFIRI with AG-013736 or avastin in patients with metastatic colorectal cancer after failure of one first line regimen. Clinicatrials.gov 2008 April 07. http://clinicaltrials.gov/ct2/show/NCT00615056. Accessed 15 Oct 2009
43. Randomized study of gemcitabine plus AG-013736 versus gemcitabine for advanced pancreatic cancer. Clinicaltrials.gov 2007 May 07. http:// clinicaltrials.gov/ct2/show/NCT00471146. Accessed 15 Oct 2009
44. Axitinib as second line therapy for metastatic renal cell cancer: Axis trial. Clinicaltrials.gov 2009. http://clinicaltrials.gov/ct2/show/NCT00678392. Accessed 15 Oct 2009
45. MW Karaman S Herrgard DK Treiber, et al. 2008 A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 127 132 10.1038/nbt1358 1:CAS:528:DC%2BD1cXisFGlsQ%3D%3D 18183025
46. Rixe O, Dutcher JP, Motzer RJ (2008) Association between diastolic blood pressure ≥90 mmHg and efficacy in patients with metastatic renal cell carcinoma receiving axitinib (AG-013736). ESMO 2008 Meeting abstract
47. DT Alexandrescu R McClure H Farzanmehr CA Dasanu 2008 Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib J Clin Oncol 26 4047 4048 10.1200/JCO.2008.18.3525 18711201
48. BY Tam K Wei JS Rudge, et al. 2006 VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis Nat Med 12 793 800 10.1038/nm1428 1:CAS:528:DC%2BD28Xms1eksLs%3D 16799557 (Pubitemid 44050069)
49. AT Boutin A Weidemann Z Fu, et al. 2008 Epidermal sensing of oxygen is essential for systemic hypoxic response Cell 133 223 234 10.1016/j.cell.2008.02. 038 1:CAS:528:DC%2BD1cXltlWnurc%3D 18423195